How to Verify FDA Section 361 HCT/P Compliance for Allografts

To verify FDA Section 361 HCT/P compliance for allografts, medical practices must confirm the source tissue bank’s active registration in the FDA Human Cell and Tissue Establishment Registration (HCTERS) database, review the product’s processing standard operating procedures against minimal manipulation criteria, and audit marketing materials for homologous use claims under 21 CFR 1271.10(a). Additionally, procurement managers should collect lot-specific infectious disease screening records, verify American Association of Tissue Banks (AATB) accreditation, and ensure the distributor has no unresolved FDA untitled or warning letters.

For practice administrators and clinical directors integrating biologics such as amniotic allografts, Wharton's Jelly, or cord blood into their service lines, regulatory due diligence is a foundational operational requirement. Because the FDA does not issue premarket approval letters for Section 361 products, the burden of compliance rests on the manufacturer's adherence to federal criteria—and on the purchasing practice's ability to audit that adherence before bringing products into the clinic.

Understanding the Regulatory Baseline: Section 361 vs. Section 351

Human cells, tissues, and cellular and tissue-based products (HCT/Ps) are regulated under Title 21 of the Code of Federal Regulations (CFR) Part 1271. The regulatory framework bifurcates these products into two distinct pathways under the Public Health Service (PHS) Act: Section 361 and Section 351.

Section 351 products are regulated as drugs, devices, or biological products. They require an Investigational New Drug (IND) application for clinical trials and a Biologics License Application (BLA) for commercial distribution. Conversely, Section 361 products are regulated solely under 21 CFR Part 1271 and do not require premarket FDA approval, provided they meet all four criteria outlined in 21 CFR 1271.10(a):

1. Minimal Manipulation: For structural tissue, processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For cells or nonstructural tissues, processing must not alter the relevant biological characteristics.
2. Homologous Use: The product must perform the same basic function or functions in the recipient as in the donor, as reflected by the labeling, advertising, and other objective intent of the manufacturer.
3. No Combination Articles: The HCT/P must not be combined with another article, with limited exceptions for water, crystalloids, or sterilizing, preserving, or storage agents that raise no new clinical safety concerns.
4. Systemic Effect: The product must not have a systemic effect and must not be dependent upon the metabolic activity of living cells for its primary function—unless it is for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

When a vendor claims their allograft is a "361 product," they are self-designating that their tissue processing and marketing meet all four of these standards. Knowing how to verify FDA Section 361 HCT/P compliance for allografts requires looking past a sales representative's verbal assurances and auditing the underlying documentation.

Step-by-Step Vendor Audit Checklist for Practice Managers

Practice administrators responsible for procurement, risk management, and vendor onboarding should implement a standardized compliance checklist before signing purchasing agreements.

• Verify Active FDA Establishment Registration (FEI Number): Request the processing tissue bank’s FDA Establishment Identifier (FEI) number and look it up directly in the public FDA Human Cell and Tissue Establishment Registration (HCTERS) database. Confirm that the registration status is "Active," verify the exact types of tissues listed on the registration, and note that registration simply means the facility notified the FDA of its operations—it does not constitute FDA approval of the product.
• Search the FDA Inspection and Compliance Databases: Cross-reference the manufacturer and distributor names in the FDA Data Dashboard and Warning Letters database. Verifywhether the facility has received FDA Form 483 inspectional observations, Untitled Letters, or Warning Letters citing violations of current Good Tissue Practice (cGTP) or unlawful marketing of unapproved biological drugs.
• Audit Product Labeling and Objective Intent (Homologous Use): Review all package inserts, brochures, websites, and white papers provided by the vendor. Under 21 CFR 1271.10(a)(2), the FDA evaluates "objective intent" based on vendor marketing. If a vendor markets an amniotic membrane or Wharton's Jelly product with specific therapeutic claims to treat systemic diseases or regenerate specific orthopedic structures rather than serving as a structural barrier, covering, or cushion, the FDA may deem it a Section 351 drug.
• Review Processing Summaries (Minimal Manipulation): Request documentation explaining how the tissue is processed from recovery to final packaging. For structural tissues like amniotic membrane or umbilical cord matrix, micronization, enzymatic digestion, or processes that alter the extracellular matrix's physical integrity may cross the regulatory line into more than minimal manipulation.
• Confirm Donor Eligibility and Infectious Disease Testing: Under 21 CFR Part 1271 Subpart C, tissue banks must screen donors for relevant communicable disease agents and diseases (RCDADs). Require a sample Certificate of Analysis (CoA) or package insert demonstrating CLIA-certified lab testing for HIV-1/2, Hepatitis B, Hepatitis C, Treponema pallidum (syphilis), HTLV-I/II, West Nile Virus, and sterility/endotoxin clearance.
• Check Third-Party Accreditation and State Licenses: Verify whether the source tissue bank holds accreditation from the American Association of Tissue Banks (AATB), which enforces rigorous operational standards beyond baseline federal requirements. Additionally, verify that the vendor holds required state-level distribution or tissue bank licenses in jurisdictions such as New York, California, Florida, Maryland, or Texas.

Clinical Perspective: Evaluating Tissue Integrity and Patient Safety

While practice managers focus on documentation, supply chain continuity, and legal risk, the clinical leadership—such as orthopedic doctors and pain management doctors—must evaluate how regulatory compliance translates to patient safety and clinical utility.

From a physician's standpoint, adherence to current Good Tissue Practice (cGTP) under 21 CFR Part 1271 Subpart D directly impacts the biological integrity of the allograft. Improperly processed or stored tissues pose serious risks of microbial contamination, immunogenic reactions, or structural degradation. Physicians should review the sterilization methodology used by the tissue bank—such as gamma irradiation, electron beam (E-beam) sterilization, or aseptic processing—and understand how that method affects the structural matrix of the tissue.

Furthermore, clinicians must maintain clear boundaries between a manufacturer's regulatory classification and their own clinical documentation. While licensed physicians have the authority to practice medicine and utilize products based on their clinical judgment, chart notes, informed consent forms, and clinic marketing materials should accurately describe the allograft's structural or homologous function. Aligning clinical documentation with compliant supply chain practices protects both patient outcomes and the medical license of the treating provider.

Operationalizing Compliance: Receiving, Storage, and Tracking

Regulatory compliance does not end once a vendor passes your initial procurement audit. Practice managers must establish internal standard operating procedures (SOPs) for handling allografts within the clinic.

Cold Chain Verification and Storage

Depending on the processing method, allografts may be shipped at ambient room temperature, refrigerated, or cryopreserved on dry ice or liquid nitrogen vapor. Staff must be trained to inspect shipping containers immediately upon arrival, verify that temperature indicators have not been breached, and log the receipt temperature before transferring the biologics into calibrated, temperature-monitored clinic freezers or refrigerators.

Adverse Event and Tissue Tracking Logs

Under 21 CFR 1271.290, facilities must maintain a tracking system that enables the tracking of all HCT/Ps from the donor to the consignee or final disposition. At the clinic level, this means maintaining a dedicated tissue logbook (physical or integrated into your EHR) that links the specific allograft serial or lot number to the patient's medical record. Vendors typically provide peel-off tracking labels inside the packaging; one label should go into the patient chart, one into the clinic's master biologic log, and the recipient information card should be returned to the tissue bank to complete the chain of custody.

What This Means for Your Practice

Establishing a formal compliance protocol protects your practice from regulatory disruption, financial liability, and supply chain interruptions. Practice administrators should take the following concrete actions:

1. Audit Current Inventory: Collect the FEI numbers and package inserts for all allografts currently in your clinic and verify their status in the FDA HCTERS database.
2. Standardize Vendor Onboarding: Require any prospective biologic supplier to submit their FDA registration, AATB accreditation certificate, sample CoA, and processing summary before allowing them to pitch to your clinical staff.
3. Review Clinic Marketing: Audit your practice's website, patient brochures, and consent forms to ensure your patient-facing language aligns with compliant regulatory frameworks.
4. Partner with Vetted Distributors: Work with established medical distributors who conduct upstream regulatory vetting on the tissue banks they represent.

If your practice is evaluating compliant biologic options or seeking to streamline your regenerative procurement workflow, explore our about page to learn how Dallas Regenerative Solutions supports licensed providers, or reach out via our contact page to schedule an operational consultation.